1. Current Status of the 340B Rebate Model Lawsuit
On October 9, 2026, AHA, Maine Hospital Association, and four hospitals challenged the revised pilot in the U.S. District Court for the District of Maine. Their complaint requests declaratory and injunctive relief. As of October 12, the reviewed sources confirm the filing but do not establish an order suspending the revised program.
Earlier Court Relief Applied to an Earlier Pilot
A court blocked the pilot originally scheduled for January 2026. HHS withdrew that version, and the court vacated its notices and manufacturer approvals in February 2026.
HRSA subsequently announced a revised program with approved plans scheduled to start in January 2027. Hospitals should distinguish the earlier court relief from any orders addressing this new program.
2. Changes to Purchasing and Rebate Timing
The revised pilot shifts certain drug purchases from upfront 340B discounts to wholesale acquisition cost, or WAC, followed by rebate requests. HRSA states that the ceiling price and eligibility requirements remain unchanged.
Scope and Submission Deadlines
Exposure depends on approved manufacturer plans covering selected drugs in the 2026 and 2027 Medicare negotiation cycles. Drugs without an approved rebate plan retain upfront discounts. Reviewing the applicable plans is therefore part of assessing healthcare regulations.
Claims generally must reach the submission platform within 45 calendar days of dispensing, subject to specified exceptions. Manufacturers must pay or issue a documented denial within 10 calendar days after a completed submission. Missing information can restart the clock when the hospital completes its submission.
That deadline does not measure the entire funding gap between purchasing a drug and receiving its rebate.
3. Legal Grounds for the AHA Challenge
The 340B lawsuit challenges federal agency action under the Administrative Procedure Act. Plaintiffs allege inadequate consideration of administrative costs, financing burdens, less costly alternatives, and hospitals’ reliance on upfront discounts. These remain allegations rather than findings against the revised pilot.
HRSA cites transparency and program-integrity benefits and implementation safeguards. The administrative law dispute concerns whether the agency adequately evaluated relevant factors and explained its decision.
A temporary injunction would address implementation while litigation proceeds. A final merits ruling would address the challenged action’s legality. Hospitals should examine each order’s scope, effective date, and any appellate stay before revising their plans.
4. Budget and Operational Preparation for 2027
Hospital teams can model the scheduled rollout alongside a postponement scenario. The analysis should separate rebates expected to be recovered from administrative expenses and financing costs.
| Planning area | Records to review | Purpose |
|---|---|---|
| Affected spending | Approved plans and purchasing volumes | Identify drug exposure |
| Cash flow | Wholesaler terms and collection forecasts | Estimate temporary funding needs |
| Claims processing | Submission logs and denial records | Find delays and errors |
| Implementation | Vendor terms and staffing estimates | Identify added expenses |
Affected spending
- Records to reviewApproved plans and purchasing volumes
- PurposeIdentify drug exposure
Cash flow
- Records to reviewWholesaler terms and collection forecasts
- PurposeEstimate temporary funding needs
Claims processing
- Records to reviewSubmission logs and denial records
- PurposeFind delays and errors
Implementation
- Records to reviewVendor terms and staffing estimates
- PurposeIdentify added expenses
Teams reviewing liquidity solutions should compare collection assumptions with payment obligations, borrowing limits, and financial covenants.
HRSA requires manufacturers to bear submission-platform costs. Hospitals may still face internal integration and staffing expenses. Assign responsibility for submitting claims, correcting errors, reconciling payments, and retaining records.
5. Additional Questions for Hospital Teams
Pricing dates and inventory arrangements create distinct reconciliation issues.
Which Date Determines the Rebate’S Ceiling Price?
HRSA uses the dispensing date, or date of service, rather than the purchasing date. Hospitals should retain that date when reconciling transactions across quarters.
Can Dispensing Precede a Replenishment Purchase?
Yes. HRSA permits dispensing from neutral inventory before a subsequent WAC replenishment purchase. Hospitals must retain auditable purchase and rebate records and use the designated purchasing account for eligible transactions.
6. Legal Review When Implementation Assumptions Change
Review becomes useful when a court order changes rollout assumptions, manufacturer instructions appear inconsistent with an approved plan, or vendor responsibilities remain unclear.
The relevant materials include approved plans, purchasing records, workflow documents, vendor agreements, and budget assumptions. An attorney can assess the disputed requirements or order while finance and pharmacy teams evaluate the operational consequences.
12 Oct, 2026
